Compare NetFlix Inc (NFLX) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetFlix Inc vs TransMedics Group Inc — how do they compare? NetFlix Inc trades at $76.46 (market cap $319.67B), while TransMedics Group Inc trades at $85.89 (market cap $3.06B). The key difference: NetFlix Inc is far larger — about 104.5× TransMedics Group Inc's market cap, and TransMedics Group Inc is trading nearer its 52-week high, NetFlix Inc nearer its low. Which is the better fit depends on your goals.
| NFLX | TMDX | |
|---|---|---|
Market Cap | $319.67B | $3.06B |
Sector | Consumer Cyclical | Technology |
52-Week High | $124.77 | $150.42 |
52-Week Low | $67.60 | $61.99 |
Enterprise Value | $324.85B | $3.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Netflix (NFLX) is trading at $76.03, down 2.84% on the day, amid a bearish technical signal and recent price weakness. The stock is near its 52-week low, with support at $76 and resistance at $78. Fundamentally, the company shows strong revenue growth, with 2025 revenue at $45.18 billion and net income of $10.98 billion, and has beaten EPS estimates for the last three quarters. Analyst sentiment remains largely positive with a consensus buy rating and price target of $88.95, though recent news highlights concerns over the stock's performance streak.
The outlook for NFLX is mixed; strong fundamentals and analyst optimism suggest potential upside, but technical bearishness and competitive pressures pose risks. Investors should weigh robust profitability and ad-tier expansion against market volatility and execution challenges in the streaming sector.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetFlix Inc
Netflix Inc. is an Internet subscription service for watching television shows and movies. Subscribers can instantly watch unlimited television shows and movies streamed over the Internet to their televisions, computers, and mobile devices and in the United States, subscribers can receive standard definition DVDs and Blu-ray Discs delivered to their homes.
Read more on NFLX →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
